Abstract:Our data suggest that continued use of LDA increased the risk of bleeding after ESD for colorectal tumors compared with nonuse of anticoagulant/antiplatelets. No significant difference was seen between the LDA-continued group and the LDA-interrupted group.
“…Five full-text studies were chosen for the final analysis (10,11,(24)(25)(26) (Figure 1). The Newcastle-Ottawa scale was used to assess the quality of the included studies (Table 1).…”
Section: Assessment Of the Selected Studiesmentioning
confidence: 99%
“…The five selected publications included four historical cohort studies and one case-control study (10,11,(24)(25)(26). Four studies involved gastric cancer and one involved colorectal cancer; four studies described tumor location and tumor size and two mentioned operation time and rate of perforation; all the studies were published from 2012 to 2015 (10,11,24,26) (Table 2).…”
Section: Detailed Information Of the Selected Studiesmentioning
confidence: 99%
“…Four studies involved gastric cancer and one involved colorectal cancer; four studies described tumor location and tumor size and two mentioned operation time and rate of perforation; all the studies were published from 2012 to 2015 (10,11,24,26) (Table 2). The information on age was introduced in five publications.…”
Section: Detailed Information Of the Selected Studiesmentioning
confidence: 99%
“…Five studies with data available on bleeding included 271 patients who received LDA-continued treatment for thromboembolic events before and after ESD therapies; they also included 278 controls who received LDA-interrupted treatment (10,11,(24)(25)(26). The average incidence of bleeding in the LDAcontinued group was up to 11.8% but was 5.4% in the LDA-interrupted group.…”
Section: Bleeding Complicationmentioning
confidence: 99%
“…Three of the trials with data available on bleeding included 171 patients who perioperatively received LDA-interrupted treatment and 2321 controls who did not use anticoagulant/ APT agents (10,11,26). In the no-anticoagulant/APT group, the incidence of bleeding was 4.8%, but was 5.8% in the LDAinterrupted group.…”
“…Five full-text studies were chosen for the final analysis (10,11,(24)(25)(26) (Figure 1). The Newcastle-Ottawa scale was used to assess the quality of the included studies (Table 1).…”
Section: Assessment Of the Selected Studiesmentioning
confidence: 99%
“…The five selected publications included four historical cohort studies and one case-control study (10,11,(24)(25)(26). Four studies involved gastric cancer and one involved colorectal cancer; four studies described tumor location and tumor size and two mentioned operation time and rate of perforation; all the studies were published from 2012 to 2015 (10,11,24,26) (Table 2).…”
Section: Detailed Information Of the Selected Studiesmentioning
confidence: 99%
“…Four studies involved gastric cancer and one involved colorectal cancer; four studies described tumor location and tumor size and two mentioned operation time and rate of perforation; all the studies were published from 2012 to 2015 (10,11,24,26) (Table 2). The information on age was introduced in five publications.…”
Section: Detailed Information Of the Selected Studiesmentioning
confidence: 99%
“…Five studies with data available on bleeding included 271 patients who received LDA-continued treatment for thromboembolic events before and after ESD therapies; they also included 278 controls who received LDA-interrupted treatment (10,11,(24)(25)(26). The average incidence of bleeding in the LDAcontinued group was up to 11.8% but was 5.4% in the LDA-interrupted group.…”
Section: Bleeding Complicationmentioning
confidence: 99%
“…Three of the trials with data available on bleeding included 171 patients who perioperatively received LDA-interrupted treatment and 2321 controls who did not use anticoagulant/ APT agents (10,11,26). In the no-anticoagulant/APT group, the incidence of bleeding was 4.8%, but was 5.8% in the LDAinterrupted group.…”
ESD was performed safely, and death related to gastric cancer was prevented in super-elderly patients with comorbidities, regardless of the degree of the disease. However, patients with comorbidities are at a high risk of poor prognosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.